Immunotherapy for type 1 diabetes: what’s in the pipeline? – The Pharmaceutical Journal
The Pharmaceutical Journal |
Immunotherapy for type 1 diabetes: what's in the pipeline?
The Pharmaceutical Journal Another major reason for the absence of licensed immunotherapies is that clinicians have not been keen to refer T1D patients on to trials of this class of drugs, says Dayan, who also heads the clinical engagement and training core of the T1D UK … |
